AAA
SPRY icon

Affinity Asset Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Affinity Asset Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-400,000
Closed -$5.8M – 98
2024
Q3 		$5.8M Buy
+400,000
New +$4.76M 0.79% 40

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Affinity Asset Advisors's SPRY Position: Q4 2025 in Review

Affinity Asset Advisors sold out of ARS Pharmaceuticals (SPRY) in Q4 2025, closing a stake of 2,500 shares — an estimated $25.1K sold.

Affinity Asset Advisors first reported a position in SPRY in Q2 2022 and held it in 2 quarters. The position peaked at $721K in Q2 2022. 189 funds tracked by Wall St. Rank hold SPRY as of Q4 2025.

  • Affinity Asset Advisors reported no remaining ARS Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Affinity Asset Advisors sold 2,500 ARS Pharmaceuticals shares in Q4 2025, an estimated $25.1K.
  • Affinity Asset Advisors first reported a position in ARS Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Affinity Asset Advisors's ARS Pharmaceuticals position peaked at $721K in Q2 2022.
  • 189 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2025.

Based on Affinity Asset Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.